Panacea Biotec

Sector: Pharma & Healthcare (Vaccine Plant)  |  HQ: India  |  Founded: Not separately disclosed  |  Employees: Not separately disclosed

Listed as: Privately held  | 

Company overview

Panacea Biotec operates in the pharma & healthcare segment of the Indian market, with a presence noted in the vaccine plant category. The company is among the recognised participants in this segment alongside other Indian and multinational players. Operations follow the standard Companies Act 2013 disclosure framework where Panacea Biotec is incorporated as a private or public limited company under Indian law, with statutory audit, GST registration under the CGST Act 2017, and applicable sectoral compliance under FSSAI, BIS, MoEF, or sectoral regulators as relevant to the activity. The competitive set in vaccine plant includes pan-India brands, regional players, and multinational subsidiaries operating in India through wholly-owned or joint-venture structures.

Recent developments

Nov 2025 – Apr 2026

Panacea Biotec's dengue vaccine candidate DengiAll reached a critical inflection point with the completion of Phase III enrolment in early January 2026, driving significant investor interest and a sharp re-rating of the stock—shares surged 9–14% in a single day on the news [5,8,2]. The milestone drew international attention, with Japan Times reporting India moving closer to its first dengue vaccine after 17 years of development [3,6]; the company subsequently entered the final trial phase, cementing DengiAll's near-term commercial prospects [2].

Beyond its flagship vaccine pipeline, Panacea Biotec expanded into adjacent consumer health segments in September 2025 with the launch of a toxin-free baby care line and infant milk substitute in India [7]. More recently, the company secured a Letter of Award (LoA) worth Rs 20.79 crore from CMSS (Central Medical Services Society) in April 2026, indicating successful penetration into public procurement channels [9]. A senior management appointment was also formalised in November 2025, with Bal Krishan Saini designated as a Senior Management Personnel [1].

Sources (8)

1. Panacea Biotec shares jump 14% as dengue vaccine enters final trial phase - Fortune India · Fortune India · Thu, 08 Jan 2026
2. India moves closer to dengue vaccine as final trials underway - The Japan Times · The Japan Times · Fri, 06 Mar 2026
3. Panacea Biotec completes enrolment for Phase III clinical trial of dengue vaccine DengiAll - CNBC TV18 · CNBC TV18 · Wed, 07 Jan 2026
4. India’s first dengue vaccine has been in the making for 17 yrs. DengiAll has the world excited - ThePrint · ThePrint · Wed, 07 Jan 2026
5. Panacea Biotec Launches Toxin-Free Baby Care Line and Infant Milk Substitute in India - scanx.trade · scanx.trade · Wed, 24 Sep 2025
6. Panacea Biotec up 9% on completing Phase III enrollment for DengiAll trial - Business Standard · Business Standard · Thu, 08 Jan 2026
7. Panacea Biotec rises on bagging LoA worth Rs 20.79 crore from CMSS - Investment Guru · Investment Guru · Mon, 13 Apr 2026
8. Bal Krishan Saini designated as Senior Management Personnel of Panacea Biotec Pharma - Medical Dialogues · Medical Dialogues · Fri, 14 Nov 2025

Financial performance and recent trajectory

Disclosed revenue (FY25): Not separately disclosed in segment-wise FY 2024-25 reporting.

Competitive position

Panacea Biotec occupies a position in the vaccine plant category alongside other listed and unlisted Indian players. Competitive intensity in the segment is shaped by raw material cost cycles, distribution depth, branded versus unbranded share, and the regulatory framework governing manufacturing, FSSAI labelling (for food), BIS standards (for engineering goods), or sectoral norms. The principal competitive moats in this category are typically scale, distribution reach, brand trust, and integrated procurement. KAMRIT's project report on vaccine plant benchmarks new entrant economics against the listed peer cost structure including capex per tonne (or per unit of output), working capital intensity, gross margin band, and the EBITDA delta between organised and unorganised participants.

Key risks

Input cost volatility in the vaccine plant value chain Competitive intensity from larger Indian groups and multinational subsidiaries Regulatory tightening under FSSAI, BIS, environmental norms, or labour codes

Outlook

Panacea Biotec is a participant in the Indian vaccine plant category, which forms part of the broader Pharma & Healthcare space. The Indian vaccine plant market continues to evolve with rising organised share, premiumisation, distribution expansion, and a regulatory architecture covering the Companies Act 2013, the Income Tax Act 1961, the CGST Act 2017, the Legal Metrology Act 2009, and sectoral statutes including the Food Safety and Standards Act 2006 (for food and beverage subsegments), the Drugs and Cosmetics Act 1940 (for pharmaceutical or healthcare adjacencies), the Environment Protection Act 1986 (for emissions and effluents), and labour codes consolidated under the four 2020 labour codes. In KAMRIT's project report framework for this category, the competitive set typically includes pan-India branded leaders, multinational subsidiaries, mid-sized regional players, and a long tail of MSME participants. The structural attractiveness of the category for new entrants is a function of (a) market growth rate, (b) the share that remains with unorganised or fragmented operators, (c) the cost of regulatory compliance, and (d) the capex intensity of plant and machinery. The KAMRIT bankable DPR for this category structures a new entrant's economics against this competitive landscape. For Panacea Biotec specifically, public-domain disclosures provide a baseline view of operations, but segment-wise revenue, EBITDA, capacity utilisation, and forward capex plans are not separately broken out in many cases. Where the company is part of a listed group, the SEBI LODR and the Companies Act 2013 governance framework apply, with statutory audit conducted under SA 700 and CARO 2020 reporting. Where the company is unlisted, the Companies Act 2013 framework continues to govern with reduced public disclosure. The risk and opportunity outlook for Panacea Biotec mirrors the broader vaccine plant category dynamics. Demand-side drivers include rising household consumption, urbanisation, organised retail expansion, and policy support including PLI schemes (where applicable to the segment). Supply-side risks include input cost volatility, regulatory tightening, environmental compliance escalation, and competitive intensity from larger groups or imports. Management quality, balance sheet strength, distribution depth, and the capex execution track record are the differentiators within the peer set. KAMRIT's research desk maintains a baseline reference for Panacea Biotec as a peer benchmark within the vaccine plant category. For investors, lenders, or new entrant promoters seeking a fuller assessment of Panacea Biotec, KAMRIT's deep-dive company profile engagement covers financial trajectory, capacity and capex, distribution and customer concentration, regulatory exposure, and the competitive position with named peers.

KAMRIT point of view

Building or competing with Panacea?

KAMRIT advises promoters, family offices, and global enterprises evaluating greenfield entry into the pharma & healthcare (vaccine plant) sector. Our Bankable DPR with Cost Model and ROI benchmarks your project economics against the listed-company cost structure of Panacea and peers. The Execution Partnership tier covers everything from incorporation through commissioning. A 20-minute scoping call with our partners is free.

View all 1 related project report → Book a scoping call

Related KAMRIT project reports

These reports use Panacea Biotec in benchmarking and competitive analysis sections.

Disclaimer: This profile is compiled by KAMRIT Financial Services LLP for educational and benchmarking purposes only. It is not investment advice, a recommendation to buy or sell securities, or a solicitation. Stock data is provided by Yahoo Finance and may be delayed by up to 20 minutes. Company financial commentary draws on publicly available filings, exchange disclosures, and KAMRIT industry research. Readers should consult a SEBI-registered investment adviser before making investment decisions. KAMRIT is a financial services and compliance firm, not a SEBI-registered investment adviser.